Cover Image

Beneficial effects of milk kefir in patients with chronic hepatitis c virus infection

Basant M. Morsy, Ayman M. Mahmoud*, Mohamed I. Zanaty, Adel Abdel-Moneim, Mohamed A. Abo-Seif

Abstract


The current study was designed to evaluate the beneficial therapeutic effects of milk kefir in Egyptian hepatitis C virus (HCV) patients. Thirty volunteer patients with proven HCV and fifteen age matched healthy subjects were included in this study. Exclusion criteria included patients on interferon therapy, infection with hepatitis B virus, drug-induced liver diseases, advanced cirrhosis, hepatocellular carcinoma or other malignancies, blood picture abnormalities and major severe illness. The included subjects were divided into three groups as follows: Group 1 served as healthy, Group 2 served as HCV control and Group 3 HCV patients received 250 ml freshly prepared milk kefir twice daily for one month. Liver function enzymes, albumin, total bilirubin, prothrombin time and concentration, international normalized ratio, lipid profile and viral load were all assessed at baseline and at the end of the study. Milk kefir exhibited marked therapeutic benefits in HCV patients through decreasing viral load, alleviating the altered liver function and improvement of lipid profile. The ameliorative effects of milk kefir in HCV patients may be attributed to its antioxidant, anti-inflammatory and immune-stimulatory effects.

Keywords


Hepatitis C Virus; Kefir; Viral Load.

Full Text:

PDF

References


Calland N, Dubuisson J, Rouillé Y, Séron K, Hepatitis C Virus and Natural Compounds: A New Antiviral Approach? Viruses, 2012, 4, 2197-2217.

World Health Oranization. Hepatitis C., June 2011. http://www.who.int/mediacentre/factsheets/fs164/en/index.html.

Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL et al., ., Management of hepatitis C virus genotype 4: recommendations of an international expert panel, J Hepatol, 2011, 54, 1250-1262.

Alter MJ, Epidemiology of hepatitis C virus infection, World J Gastroenterol, 2007, 13, 2436-2441.

Lavanchy D, Evolving epidemiology of hepatitis C virus, Clin Microbiol Infect, 2011, 17, 107-115.

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group, N Engl J Med, 1998, 339, 1485-1492.

Di Bisceglie AM, Hoofnagle JH, Optimal therapy of hepatitis C, Hepatology, 2002, 36, S121–S127.

Vermehren J, Sarrazin C, New hepatitis C therapies in clinical development, Eur J Med Res, 2011, 16, 303-314.

Kneifel W, Mayer HK, Vitamin profiles of kefirs made from milks of different species, International Journal of Food Science Technology, 1991, 26, 423-428.

Otles S, Cagindi O, Kefir: A Probiotic Dairy-Composition, Nutritional and Therapeutic Aspects, Pak J Nutr, 2003, 2(2), 54–59.

Liu JR, Wang SY, Lin YY, Lin CW, Antitumor activity of milk kefir and soy milk kefir in tumor-bearing mice, Nutr Cancer, 2002, 44, 183-187.

Guven A, Gulmez M, The effect of kefir on the activities of GSH-Px, GST, CAT, GSH and LPO levels in carbon tetrachloride-induced mice tissues, J Vet Med B Infect Dis Vet Public Health, 2003, 50, 412-416.

Vinderola G, Perdigon G, Duarte J, Farnworth E, Matar C, Effects of the oral administration of the products derived from milk fermentation by kefir microflora on immune stimulation, J Dairy Res, 2006, 73, 472-479.

Lopitz-Otsoa F, Rementeria A, Elguezabal N, Garaizar J. Kefir: A symbiotic yeasts-bacteria community with alleged healthy capabilities, Rev Iberoam Micol, 2006, 23, 67-74.

Hertzler SR, Clancy SM, Kefir improves lactose digestion and tolerance in adults with lactose maldigestion, J Am Diet Assoc, 2003, 103, 582-587.

Schumann G, Klauke R, New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: preliminary upper reference limits obtained in hospitalized subjects, Clin Chem Acta 2003, 327(1-2), 69-79.

Teitz N, Fundam. Of Clin. Chem., W. B. Saunders Co., Philadelphia, PA 1986.

IFCC, Methods for the measurement of catalytic concentration of enzymes, J Clin Chem Clin Biochem, 1980, 18, 521-534.

Persijn JP, van der Slik W, A new method for the determination of gamma-glutamyltransferase in serum, J Clin Chem Clin Biochem, 1976, 14, 421-427.

Webster D, A study of the interaction of bromcresol green with isolated serum globulin fractions, Clin Chim Acta, 1974, 53, 109-115.

Kaplan LA, Glucose. In: Kaplan LA, Pesce AJ: Clinical chemistry: theory, analysis, and correlation. St. Louis, MO: Mosby; 1984, 1032-1036.

Wanger C, Dati F, Prothrombin time (PT) test. In: Thomas L (ed): Cilinical laboratory diagnostics. Frankfurt: TH books Verlagsges.; 1998, 599-601.

Allain CC, Poon LS, Chan CS, Richmond W, Fu PC, Enzymatic determination of total serum cholesterol, Clin Chem, 1974, 20(4), 470-475.

Tietz NW, Clinical guide to laboratory tests, 2nd ed. Philadelphia, PA: W.B. Saunders Co., 1990.

Friedewald WT, Estimation of concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge, Clin Chem, 1972, 18(7), 499-502.

Nobert WT, Clinical guide to laboratory tests, 3rd edition. Philadelphia, PA: W.B. Saunders Co., 1995.

Ross R, The pathogenesis of atherosclerosis. In: Braunwald E, editor. Heart disease, 4th ed. Philadelphia, PA: W. B. Saunders Co; 1992, 1106-1124.

Abdel-Moneim A, Morsy BM, Mahmoud AM, Abousief MA, Zanaty M, Benificial therapeutic effects of Nigella sativa and/or Ginger officinale in HCV patients in Egypt, EXCLI J, 2013, 12, 943-955.

Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nourani MR, Khani S, Alavian SM, Probiotic as a novel treatment strategy against liver disease, Hepat Mon, 2013, 13(2), e7521.

Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE, Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis, Hepatology, 2005, 41(6), 1376-1382

Ramaiah S, A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters, Food Chem Toxicol, 2007, (45), 1551-1557.

Gill HS, Stimulation of the immune system by lactic cultures, Intern Dairy J, 1988, 8, 535-544.

Murofushi M, Mizuguchi J, Aibara K, Matuhasi T, Immunopotentiative effect of polysaccharide from kefir grain, KGF-C, administered orally in mice, Immunopharmacol, 1986, 12, 29-35.

Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, Testa E, Risso D, Colla G, Testa R, MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study, Gut, 2003, 52(1), 134-139.

Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP, Association of diabetes mellitus and chronic hepatitis C virus infection, Hepatol, 1999, 29, 328-333.

Nagao Y, Sata M, Serum albumin and mortality risk in a hyperendemic area of HCV infection in Japan, Virol J, 2010, 7, 375.

Kotoh K, Nakamuta M, Fukushima M, Matsuzaki C, Enjoji M, Sakai H, Nawata H, High relative fat-free mass is important for maintaining serum albumin levels in patients with compensated liver cirrhosis, World J Gastroenterol, 2005, 11, 1356-1360.

Alter MJ, Mast EE, The epidemiology of viral hepatitis in the United States, Gastroenterol Clin North Am, 1994, 23, 437.

Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC, Hepatitis C virus infection and the risk of coronary disease, Clin Infect Dis, 2009, 49(2), 225-232.

Liu JR, Wang SY, Chen MJ, Chen HL, Yueh PY, Lin CW, Hypocholesterolaemic effects of milk-kefir and soyamilk-kefir in cholesterol-fed hamsters, Br J Nutr, 2006, 95, 939-946.




DOI: http://dx.doi.org/10.21746/ijbio.2014.06.0011

Refbacks

  • There are currently no refbacks.




Copyright (c) 2014 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.